



January 24, 2025

**RE: Support for LD107 – An Act to Require Health Insurance Coverage for Biomarker Testing**

Dear Honorable Members of the Maine Senate Health Coverage, Insurance, & Financial Services Committee:

The National Comprehensive Cancer Network® (NCCN®) appreciates the opportunity to comment on LD107, an act relating to coverage for biomarkers testing. Biomarkers Testing is of paramount importance as it relates to NCCN's mission of improving and facilitating, quality, effective, equitable, and accessible cancer care and prevention. NCCN will focus our supportive comments on the importance of comprehensive biomarker testing for residents of Maine and the role of clinical practice guidelines in determining appropriate care.

**NCCN Background**

As an alliance of 33 leading academic cancer centers in the United States, NCCN® is a developer of authoritative information regarding cancer prevention, screening, diagnosis, treatment, and supportive care that is widely used by clinical professionals and payers alike. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a comprehensive set of guidelines detailing the sequential management decisions and interventions that currently apply to 97 percent of cancers affecting patients in the United States. NCCN Guidelines® and Library of Compendia products help ensure access to appropriate care and are used by payers representing more than 85% of covered lives in the United States including CMS. NCCN imposes strict policies to shield the guidelines development processes from external influences. The guidelines development is supported exclusively by the Member Institutions' dues and does not accept any form of industry or other external financial support for the guidelines development program. The NCCN Guidelines are updated at least annually in an evidence-based process integrated with the expert judgment of multidisciplinary panels of expert physicians from NCCN Member Institutions. The NCCN Guidelines are transparent, continuously updated, available free of charge online for non-commercial use and are available through a multitude of health information technology (HIT) vendors.

**NCCN Biomarkers Compendium®**

The NCCN Guidelines® include biomarkers used for the purposes of diagnosis, screening, monitoring, surveillance, prediction, therapeutic decision-making and prognostication. The NCCN Biomarkers Compendium® contains biomarker information derived directly from the NCCN Guidelines to support decision-making around the use of biomarker testing in patients with cancer and is intended to be a resource for payers, providers, and health care entities navigating the rapidly changing evidence base for medically necessary biomarker testing in oncology. Information is provided in a searchable database that is updated continuously in conjunction with the NCCN Guidelines® to remain evergreen. In addition to providing information regarding clinical indication(s) for specific biomarker testing, the NCCN Biomarkers Compendium provides essential details for testing methodologies recommended within the NCCN Guidelines.

**Biomarker Testing Impact on Cancer Care Outcomes**

Numerous independent studies have found adherence to NCCN Guidelines® improves care delivery and outcomes for patients with cancer, including at least one study demonstrating that access to guideline adherent biomarker testing can improve overall survival with appropriately utilized targeted therapy in the first-line setting and later lines of treatment.<sup>1</sup> Guideline adherence for both treatment and biomarker testing has also been shown across numerous studies to decrease costs to payers and patients.<sup>2,3,4,5</sup> Additionally, the majority of newly approved cancer therapies in recent years were biomarker-specific treatments requiring accompanying biomarker testing to determine their potential role in a given treatment plan.<sup>6,7</sup> Non-adherence to guidelines has also been identified as a key contributor to inequities in care outcomes across race and ethnicity with some studies finding these disparities greatly reduced or eliminated when guideline adherent care is received.<sup>8,9</sup> Adherence to nationally-recognized guidelines improves care outcomes including quality of life and overall survival, may reduce inequities in care outcomes, and reduces cost of care to both the payer and the patient.

Despite a wide body of literature supporting the need for guideline adherent biomarker testing, coverage, and access to appropriate biomarker testing is still widely variable leaving many patients unable to access appropriate care. A 2022 study evaluating publicly available insurance policies for biomarker testing found that 71% of plans were more restrictive than NCCN Guideline recommendations.<sup>10</sup> This critical care gap must be addressed to ensure all people can access optimal cancer care. LD107 creates coverage for appropriate biomarker testing that adheres to nationally recognized evidence-based clinical practice guidelines. As such, NCCN is pleased to support LD107.

**NCCN Supports Clinically Appropriate Biomarkers Testing**

NCCN recommends covering biomarker testing as delineated in evidence-based nationally recognized clinical practice guidelines. NCCN would like to note that the most recent versions of our Guidelines are always available on our website. As NCCN Guidelines® and the NCCN Biomarkers Compendium® are continuously updated to stay current with the evidence, NCCN encourages your committee to refer to the current recommendations and Guideline versions on the NCCN website as a health policy tool to ensure those decisions are up to date with the standard of care.

NCCN appreciates the opportunity to comment on and support LD107. We are proud to support this legislation in harmony with our coalition partners. As a nationally recognized clinical guidelines organization, NCCN is happy to serve as a resource during the legislative process. We look forward to working together to ensure access to high-quality cancer care.

Sincerely,

Crystal Denlinger, MD, FACP  
Chief Executive Officer  
National Comprehensive Cancer Network  
denlinger@nccn.org 267.622.6654

## References

- 1 Aggarwal C, Marmarelis ME, Hwang WT, et al. Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. *JCO*. 2022;40(16\_suppl):9022-9022. doi:10.1200/JCO.2022.40.16\_suppl.9022
- 2 Newcomer LN, Weininger R, Carlson RW. Transforming prior authorization to decision support. *Journal of Oncology Practice*. 2017;13(1). doi:10.1200/jop.2016.015198
- 3 Williams CP, Azuero A, Kenzik KM, et al. Guideline discordance and patient cost responsibility in medicare beneficiaries with metastatic breast cancer. *Journal of the National Comprehensive Cancer Network*. 2019;17(10):1221-1228. doi:10.6004/jnccn.2019.7316
- 4 Sapkota U, Cavers W, Reddy S, Avalos-Reyes E, Johnson KA. Total cost of care differences in National Comprehensive Cancer Center (NCCN) concordant and non-concordant breast cancer patients. *JCO*. 2022;40(16\_suppl):e18833-e18833. doi:10.1200/JCO.2022.40.16\_suppl.e18833
- 5 Sapkota U, Cavers W, Reddy S, Avalos-Reyes E, Johnson KA. Total cost of care differences in National Comprehensive Cancer Center (NCCN) concordant and non-concordant patients with colon cancer. *JCO*. 2022;40(16\_suppl):3624-3624. doi:10.1200/JCO.2022.40.16\_suppl.3624
6. York OH PharmD, MPH, BCPS, BCGP Professor, Department of Pharmacy Practice St John's University College of Pharmacy & Health Sciences Queens, New. Trends in FDA-Approved Cancer Therapies. [www.uspharmacist.com](http://www.uspharmacist.com). <https://www.uspharmacist.com/article/trends-in-fdaapproved-cancer-therapies>
7. Suehnholz SP, Kundra R, Zhang H, et al. Tracking the FDA precision oncology drug approval landscape in OncoKB. *Journal of Clinical Oncology*. 2024;42(16\_suppl):e13507-e13507. doi:[https://doi.org/10.1200/jco.2024.42.16\\_suppl.e13507](https://doi.org/10.1200/jco.2024.42.16_suppl.e13507)
8. Fang P, He W, Gomez D, Hoffman KE, Smith BD, Giordano SH, Jagsi R, Smith GL. Racial disparities in guideline-concordant cancer care and mortality in the United States. *Adv Radiat Oncol*. 2018 May 4;3(3):221-229. doi: 10.1016/j.adro.2018.04.013. PMID: 30202793; PMCID: PMC6128037.
9. Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. *Ann Am Thorac Soc*. 2020 Feb;17(2):186-194. doi: 10.1513/AnnalsATS.201901-094OC. PMID: 31672025; PMCID: PMC6993802.
- 10, Wong WB, Anina D, Lin CW, Adams DV. Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. *Personalized Medicine*. 2022;19(3):171-180. doi:10.2217/pme-2021-0174